彭布罗利珠单抗
医学
培美曲塞
卡铂
肺癌
肿瘤科
化疗
内科学
实体瘤疗效评价标准
代理终结点
癌症
顺铂
进行性疾病
免疫疗法
作者
Jair Bar,Emilio Esteban,Delvys Rodríguez‐Abreu,Santiago Ponce-Aix,Zsuzsanna Szalai,Enriqueta Felip,Maya Gottfried,Mariano Provencio,Andrew Robinson,Andrea Fülöp,Suman Bannur Rao,D. Ross Camidge,Giovanna Speranza,Steven Matthew Townson,Julie Kobie,Mark Ayers,Elisha J. Dettman,Nathan M. Hunkapiller,Robert McDaniel,Byoungsok Jung
出处
期刊:Lung Cancer
[Elsevier BV]
日期:2024-02-17
卷期号:190: 107506-107506
被引量:7
标识
DOI:10.1016/j.lungcan.2024.107506
摘要
BACKGROUND: First-line pembrolizumab plus chemotherapy has shown clinical benefit in patients with metastatic non-small cell lung cancer (NSCLC) regardless of tissue tumor mutational burden (tTMB) status. Blood tumor mutational burden (bTMB), assessed using plasma-derived circulating tumor DNA (ctDNA), may be a surrogate for tTMB. The KEYNOTE-782 study evaluated the correlation of bTMB with the efficacy of first-line pembrolizumab plus chemotherapy in NSCLC. METHODS: for 4 cycles, then pembrolizumab plus pemetrexed for ≤31 additional cycles every 3 weeks. Study objectives were to evaluate the association of baseline bTMB with objective response rate (ORR) (RECIST v1.1 by investigator assessment; primary), progression-free survival (PFS; RECIST v1.1 by investigator assessment), overall survival (OS), and adverse events (AEs; all secondary). A next-generation sequencing assay (GRAIL LLC) with a ctDNA panel that included lung cancer-associated and immune gene targets was used to measure bTMB. RESULTS: 117 patients were enrolled; median time from first dose to data cutoff was 19.3 months (range, 1.0-35.5). ORR was 40.2 % (95 % CI 31.2-49.6 %), median PFS was 7.2 months (95 % CI 5.6-9.8) and median OS was 18.1 months (95 % CI 13.5-25.6). Treatment-related AEs occurred in 113 patients (96.6 %; grade 3-5, n = 56 [47.9 %]). Of patients with evaluable bTMB (n = 101), the area under the receiver operating characteristics curve for continuous bTMB to discriminate response was 0.47 (95 % CI 0.36-0.59). Baseline bTMB was not associated with PFS or OS (posterior probabilities of positive association: 16.8 % and 7.8 %, respectively). CONCLUSIONS: AEs were consistent with the established safety profile of first-line pembrolizumab plus chemotherapy in NSCLC. Baseline bTMB did not show evidence of an association with efficacy.
科研通智能强力驱动
Strongly Powered by AbleSci AI